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HIV-1 superinfection in an HIV-2-infected woman with
subsequent control of HIV-1 plasma viremia
Abstract
A human immunodeficiency virus type 2 (HIV-2)-infected woman experienced asymptomatic
superinfection with HIV-1 subtype AG. She did not have cross-neutralizing autologous HIV-1
antibodies before and shortly after HIV-1 superinfection. This evidence supports a mechanism other
than cross-neutralizing antibodies for the mild course of HIV-1 infection in this woman.
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A human immunodeficiency virus type 2 (HIV-2)–infected
woman experienced asymptomatic superinfection with HIV-
1 subtype AG. She did not have cross-neutralizing autologous
HIV-1 antibodies before and shortly after HIV-1 superinfec-
tion. This evidence supports a mechanism other than cross-
neutralizing antibodies for the mild course of HIV-1 infec-
tion in this woman.
Interclade and intraclade superinfection with human immu-
nodeficiency virus type 1 (HIV-1) strains has been well doc-
umented during recent years. Incidence rates are estimated to
reach 3%–8% per year (with higher levels during primary in-
fection than during chronic infection), rendering superinfec-
tion a major challenge for HIV drug and vaccine design [1–
11]. In contrast, HIV-1 and HIV-2 coinfection is observed rel-
atively infrequently in regions where both strains cocirculate at
high levels [11–13]. A prospective epidemiological study from
Senegal suggested that HIV-2–infected individuals may be pro-
tected partially from HIV-1 infection [14, 15], although other
studies in West Africa could not confirm these findings [16,
17]. In addition, a variety of in vitro studies have proposed
potential protective mechanisms [14, 18–20]. A caveat of pre-
vious studies remains: HIV-1 and HIV-2 dual infections could
rarely be attributed clearly to either coinfection or superinfec-
tion, because sequential sampling to prove superinfection was
missing in most cases. Here, we describe an HIV-2–infected
woman who was unambiguously superinfected with HIV-1.
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Case report. In December 2001, a 39-year-old pregnant
woman from Benin presented to our hospital with preterm
contractions. The results of an HIV-1/2/O screening test were
reactive. Western blot analysis revealed a positive result for HIV-
2 but a negative result for HIV-1. Plasma HIV-1 RNA was
undetectable at that time (Roche Monitor HIV-1 assay, version
1.5; detection limit, 50 copies/mL). HIV-2 infection had already
been diagnosed in December 1999 (figure 1). The infant was
born by cesarean delivery in the absence of antiretroviral treat-
ment in December 2001 and remained free of HIV infection.
To monitor for HIV-2 viremia, a product-enhanced reverse
transcriptase assay [21] was performed in January 2002. Reverse
transcriptase activity of 1266 nU/mL was detected (HIV RNA
level, ∼24,000 copies/mL) [21] and was thought to be attrib-
utable to HIV-2, because the plasma HIV-1 RNA test results
were previously negative. The baseline CD4 cell count at that
time was 729 cells/mL (CD4 percentage, 48%). In May 2002,
the CD4 cell count decreased suddenly to 340 cells/mL (CD4
percentage, 26%). Subsequently, the CD4 cell count increased
to 578 cells/mL (CD4 percentage, 27%) and remained stable
(440–600 cells/mL) for the next 5 years. In November 2005, a
plasma HIV-1 RNA test was performed, the results of which
demonstrated measurable viral RNA. The assay was repeated,
and the results confirmed the reactivity. This result raised the
questions of whether this was a rare case of HIV-2 infection
that was detectable by the Roche assay [22], whether the initial
serological diagnosis of HIV-2 infection had been incorrect, or
whether the patient had HIV-1 and HIV-2 coinfection.
Sequencing of the amplicon and phylogenetic analysis re-
vealed an HIV-1 sequence related to clade A. Thus, a retro-
spective analysis of stored samples was started. Western blot
analysis from May 2002 revealed that, in addition to the pre-
vious HIV-2 infection, HIV-1 infection had been newly ac-
quired (figure 1); in addition, plasma HIV-1 RNA was detect-
able at the low level of 540 copies/mL. A plasma sample from
January 2002, a time point at which the HIV-1 Western blot
result was still negative, was also tested for HIV-1 RNA, and a
viral load of 722 copies/mL was detected. Thus, asymptomatic
primary HIV-1 infection occurred in January 2002. Subse-
quently, the HIV-1 RNA level increased to 1760 copies/mL in
October 2002, spontaneously decreased to 63 copies/mL in Jan-
uary 2005, and then oscillated between 60 and 660 copies/mL
during the entire follow-up period (until the end of July 2008).
No HIV-associated disease developed during the entire obser-
vation period of 6 years, and it was not necessary to start
antiretroviral treatment. HIV-1 proviral DNA amplifications for
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Figure 2. Line immunoassay with specimens obtained before and after
human immunodeficiency virus type 1 (HIV-1) seroconversion. All speci-
mens were tested retrospectively in parallel with strips of the same lot.
Positions of HIV-1– or HIV-2–specific envelope antibodies are shown in
bold. The specimen obtained on day 0 (in January 2002) showed sero-
positivity only for HIV-2. Seroconversion to HIV-1 is evident by the in-
duction of HIV-1–specific envelope antibodies and by an increase of the
reactivity to matrix protein p17 and endonuclease p31 in the specimen
from day 127. NEG, seronegative reaction control.
Figure 1. Synopsis of the time of events. Day 0 is defined as the day when diagnosis of human immunodeficiency virus type 1 (HIV-1) superinfection
was made (in January 2002). The logarithmic scale delineates the longitudinal plasma HIV-1 load (squares) and neutralizing antibody titers of 70%
(NT70%) and 90% (NT90%). The horizontal dotted line represents the cutoff value (!40 copies/mL) for nondetectability of any neutralizing activity
against the autologous virus isolate. CD4 cell counts are represented by triangles. In addition, sequential Western blot (WB) results for HIV-2 and
HIV-1, by the time of HIV-1 virus isolation from plasma samples, are shown to mark their overall temporal relationship.
gag and pol genes were positive. Phylogenetic analysis of the
entire gag p24 sequence revealed recombinant virus CRF02_AG.
The results of several plasma HIV-2 RNA tests remained neg-
ative, whereas HIV-2 proviral DNA was undetectable by stan-
dard polymerase chain reaction (PCR) but was detected un-
ambiguously by a high DNA input nested DNA PCR [23].
Phylogenetic analysis of the sequenced amplicon revealed HIV-
2 subtype B.
A replication-competent isolate of the superinfecting strain
was isolated after 1580 days of follow-up. Of note, no HIV-1–
neutralizing activity was detectable in the patient’s plasma sam-
ples before HIV-1 superinfection (figure 1). Thus, HIV-2 lacked
the ability to induce a protective, cross-neutralizing activity
against HIV-1. A significant anti–HIV-1–neutralizing activity
evolved after several months of HIV-1 infection, consistent with
previous reports [24, 25].
Assays used. For HIV-1 and HIV-2 antibodies, the follow-
ing assays were used: HIV-1/2/O enzyme-linked immunosor-
bent assay (for screening), Western blot analysis (Genelabs Di-
agnostics), and line immunoassay (INNO-LIA HIV I/II Score;
Innogenetics). For HIV-1 RNA, the Cobas Amplicor HIV-1
Monitor assay, version 1.5, was used. Retrospective analyses of
HIV-1 RNA in plasma samples or proviral DNA in peripheral
blood mononuclear cells (PBMCs) used in-house real-time
PCR with primers in gag and pol. For HIV-2 RNA or DNA
PCR, PCR with primers in the gag leader sequence was used
[26]. To measure reverse transcriptase activity, an ultrasensitive
particle-enhanced reverse transcriptase assay was used [21].
The superinfecting autologous HIV-1 isolate was isolated
from CD4 cells obtained after 1580 days of follow-up, and the
autologous plasma neutralization activity was measured in a
PBMC-based neutralization assay as described elsewhere [27]
.
Discussion. We report an unambiguous case of superin-
fection with HIV-1 CRF02_AG in an HIV-2–infected woman.
Although the initial HIV-1 load was low (722 copies/mL) and
peaked at only 1760 copies/mL, the sudden decrease in the
CD4 cell count in this patient is consistent with primary HIV-
1 infection and suggests that the superinfection occurred from
December 2001 through January 2002, when results of the HIV-
1 RNA assay were first positive but the results of INNO-LIA
were negative for HIV-1–specific envelope antibodies (figure
2). HIV-1 and HIV-2 coinfection could clearly be ruled out by
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identification of an HIV-2–positive Western blot result for this
patient in December 1999. Of note, the patient did not ex-
perience any symptoms or signs of an acute retroviral syn-
drome. During the following 6 years, the HIV-1 load sponta-
neously decreased and oscillated at low levels (60–660 copies/
mL), and the CD4 cell count fluctuated between 440 and 600
cells/mL (CD4 percentage, 23%–30%). It has to be considered
that the infecting HIV-1 strain, as most isolates of CRF02_AG,
contained a critical mismatch in 1 of the HIV-1 monitor primer
binding sites [28]; thus, the viral load may have been under-
estimated. Despite repeated attempts, HIV-2 RNA remained
undetectable in plasma, but persistence of HIV-2 infection
could be documented by measuring HIV-2 proviral DNA levels
in PBMCs with use of a supersensitive high-input procedure
[23]. This case illustrates that, in an HIV-2–infected patient
who encounters a sudden decrease in CD4 cell count, potential
HIV-1 superinfection needs to be verified.
Previous studies have suggested that HIV-2 infection may
partially protect patients from subsequent HIV-1 infection but
not vice versa [15, 29]. Whether this is indeed the case is still
under debate. Several clinical and basic research studies chal-
lenged these observations [16, 17], whereas other in vitro in-
vestigations located potential mechanisms by which HIV-2 in-
fection could restrict or protect patients from HIV-1 infection,
including CCR5 downregulation by HIV-2 [14], cross-reactive
anti–HIV-1 antibody induced by HIV-2 [20], higher b-che-
mokine levels in HIV-2–infected patients [19], and viral inter-
ference at the transcriptional level [18]. To test the hypothesis
that, in our patient, potentially cross-reactive anti–HIV-1 an-
tibodies might have been induced by the previous HIV-2 in-
fection, we longitudinally assessed neutralizing activity of the
patient plasma against the autologous HIV-1 virus isolate. Of
note, before and shortly after superinfection, no anti–HIV-1
plasma–neutralizing activity was detectable (figure 1). However,
optimal antibody response could not be tested, because a viral
isolate from the time of primary HIV-1 infection was not
available.
In conclusion, our case is particular in several ways. First, it
is a rare case of an unambiguously documented HIV-2 and
HIV-1 superinfection. Second, the patient had asymptomatic
acute HIV-1 infection with a low viral load, and subsequently,
HIV-1 RNA levels remained low in the absence of any treatment
for 6 years. HIV-1 superinfection only transiently led to a de-
crease in CD4 cell count, and for the entire follow-up period,
no disease progression occurred; altogether, the course of the
infection resembles chronic HIV-2 infection rather than HIV-
1 infection. We could not detect cross-neutralizing antibodies
against HIV-1 induced by HIV-2. Thus, mechanisms other than
neutralizing antibody response were most likely responsible for
this benign course of disease.
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